GPCM
ARIA

Granite Point Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Granite Point Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-466,015
Closed -$5.8M – 113
2016
Q4 		$5.8M Buy
466,015
+8,600
+2% +$104K 4.62% 2
2016
Q3 		$6.26M Buy
457,415
+26,525
+6% +$266K 2.45% 6
2016
Q2 		$3.18M Buy
+430,890
New +$3.23M 1.37% 14
2015
Q4 		$3.63M Sell
581,215
-53,557
-8% -$351K 0.54% 8
2015
Q3 		$3.71M Sell
634,772
-70,808
-10% -$545K 2.54% 7
2015
Q2 		$5.83M Sell
705,580
-194,420
-22% -$1.72M 1.7% 6
2015
Q1 		$7.42M Buy
900,000
+100,000
+13% +$739K 2.72% 4
2014
Q4 		$5.5M Buy
800,000
+100,000
+14% +$625K 2.58% 3
2014
Q3 		$3.78M Buy
700,000
+250,000
+56% +$1.46M 1.88% 7
2014
Q2 		$2.87M Sell
450,000
-198,000
-31% -$1.36M 1.97% 9
2014
Q1 		$5.22M Sell
648,000
-552,000
-46% -$4.3M 3.74% 2
2013
Q4 		$8.18M Buy
+1,200,000
New +$6.48M 1.36% 6

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Granite Point Capital Management's ARIA Position: Q1 2017 in Review

Granite Point Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 466,015 shares — an estimated $5.8M sold.

Granite Point Capital Management first reported a position in ARIA in Q4 2013 and held it in 12 quarters. The position peaked at $8.18M in Q4 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Granite Point Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Granite Point Capital Management sold 466,015 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $5.8M.
  • Granite Point Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 12 quarters.
  • Granite Point Capital Management's Ariad Pharmaceuticals Inc position peaked at $8.18M in Q4 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Granite Point Capital Management's 13F filing for Q1 2017, filed 10 May 2017.